NeoVirTech SAS and BioImmunitas enter into a collaboration to advance BioImmunitas proprietary therapeutic human recombinant protein platform (hRPP) on the antiviral market
In a recent development, Bio Immunitas announced its intentions to align with GenScript ProBio, GenScript Biotech Corporation’s subsidiary, which proactively provides end-to-end CDMO services from drug discovery to commercialisation globally.
A Joint Collaboration Between Bio Immunitas and GenScript ProBio Leads to the Development and Fast Track Manufacturing of A Novel Therapeutic Platform
In a recent development, Bio Immunitas announced its intentions to align with GenScript ProBio, GenScript Biotech Corporation’s subsidiary, which proactively provides end-to-end CDMO services from drug discovery to commercialisation globally.